Skip to main content

LCD L39513: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin

LCD L39513, Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin, is the Local Coverage Determination that Wellpoint Federal applies to claims from 10 states (CT, IL, MA, ME, MN, NH, NY, RI and others), effective 2026-04-01 and first in force 2023-08-01. The policy text runs 559 words, and its billing and coding article A59311 lists 380 ICD-10-CM codes that support medical necessity for 1 procedure code. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wellpoint Federal
States and territories
10
CT IL MA ME MN NH NY RI VT WI
Revision effective
2026-04-01
Original effective
2023-08-01
Policy text
559 words
Covered ICD-10 codes (articles)
380

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39513
ContractContractorTypeStates
06101Wellpoint FederalMAC - Part AIL
06201Wellpoint FederalMAC - Part AMN
06301Wellpoint FederalMAC - Part AWI
06102Wellpoint FederalMAC - Part BIL
06202Wellpoint FederalMAC - Part BMN
06302Wellpoint FederalMAC - Part BWI
13101Wellpoint FederalA and B and HHH MACCT
13201Wellpoint FederalA and B and HHH MACNY
13102Wellpoint FederalA and B and HHH MACCT
13202Wellpoint FederalA and B and HHH MACNY
13282Wellpoint FederalA and B and HHH MACNY
13292Wellpoint FederalA and B and HHH MACNY
14411Wellpoint FederalA and B and HHH MACRI
14211Wellpoint FederalA and B and HHH MACMA
14311Wellpoint FederalA and B and HHH MACNH
14511Wellpoint FederalA and B and HHH MACVT
14111Wellpoint FederalA and B and HHH MACME
14112Wellpoint FederalA and B and HHH MACME
14212Wellpoint FederalA and B and HHH MACMA
14312Wellpoint FederalA and B and HHH MACNH
14512Wellpoint FederalA and B and HHH MACVT
14412Wellpoint FederalA and B and HHH MACRI

Billing and coding article A59311: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59311 (Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

A59311: Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin (Billing and Coding, effective 2026-04-01)

Covered ICD-10-CM codes
380
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A59311
ICD-10-CMDescription (FY2027)
C81.00Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
C81.01Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.02Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes
C81.03Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes
C81.04Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.05Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.06Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes
C81.07Nodular lymphocyte predominant Hodgkin lymphoma, spleen
C81.08Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites
C81.09Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites
C81.10Nodular sclerosis Hodgkin lymphoma, unspecified site
C81.11Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.12Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes
C81.13Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes
C81.14Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.15Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.16Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes
C81.17Nodular sclerosis Hodgkin lymphoma, spleen
C81.18Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites
C81.19Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites
C81.20Mixed cellularity Hodgkin lymphoma, unspecified site
C81.21Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.22Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes
C81.23Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes

Procedure codes: 38240.

Coverage indications, limitations and medical necessity

Stem cell transplantation is a process in which s tem cells are harvested from either a patient’s (autologous) or donor’s (allogeneic) bone marrow or peripheral blood for intravenous infusion. Autologous s tem cell transplantation (AuSCT) is a technique for restoring stem cell s using the patient's own previously stored cells. AuSCT must be used to effect hematopoietic reconstitution following severely myelotoxic doses of chemotherapy (HDCT) and/or radiotherapy used to treat various malignancies.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a procedure in which a portion of a healthy donor's stem cells or bone marrow is obtained and prepared for intravenous infusion. Hematopoietic stem cells are multi-potent cells that give rise to all the blood cell types; these stem cells form blood and immune cells. A hematopoietic stem cell is a cell isolated from blood or bone marrow that can renew itself, differentiate to a variety of specialized cells, can mobilize out of the bone marrow into circulating blood, and can undergo programmed cell death, called apoptosis - a process by which cells that are unneeded or detrimental will self-destruct.

The Centers for Medicare & Medicaid Services (CMS) has clarified that bone marrow and peripheral blood stem cell transplantation is a process which includes mobilization, harvesting, and transplant of bone marrow or peripheral blood stem cells and the administration of high dose chemotherapy or radiotherapy prior to the actual transplant. When bone marrow or peripheral blood stem cell transplantation is covered, all necessary steps are included in coverage.

NCD 110.23 Stem Cell Transplantation covers allo-HSCT for the following conditions, when reasonable and necessary:

• Leukemia

• Aplastic Anemia

• Severe Combined Immunodeficiency disease (SCID)

• Wiskott-Aldrich Syndrome

Allo-HSCT is covered for Medicare beneficiaries with the following indications only when participating in approved prospective clinical studies meeting specific criteria under the Coverage with Evidence Development (CED) paradigm:

• Myelodysplastic Syndromes

• Multiple myeloma with Durie-Salmon Stage II or III disease, or International Staging System (ISS) Stage II or Stage III disease

• Myelofibrosis (MF) with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary disease; or

• Sickle cell disease (SCD) that is severe and symptomatic

(Please refer to CMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations Manual , Chapter 1, Part 2, §110.23 Stem Cell Transplantation)

Per the NCD, all other indications for s tem c ell transplantation not otherwise noted as covered or non-covered remain at local Medicare Administrative Contractor (MAC) discretion.

This policy describes additional locally covered indications for allo-HSCT for primary refractory or relapsed Hodgkin and non-Hodgkin lymphomas with B-cell or T-cell origin that are medically necessary in patients for whom there are no other curative intent options.

Documentation to support the reasonable and necessary nature of allo-HSCTs must speak to the serious illness of the patient, the reasons why the patient is considered to have relapsed or refractory disease, relevant clinical contextual information such as age, frailty, performance status, cardiopulmonary function, any associated organ dysfunction that could impact complications or recovery, screening for infectious diseases that could impact transplant care, nutritional status and patient specific psychosocial and financial support structures. Risk assessment scoring, such as the European Society for Blood and Bone Marrow Transplantation (EBMT) or the HCT Comorbidity Index (HCT-CI), should be strongly considered and in the case of any nationally covered indications per NCD 110.23 would of course be required.

Summary of evidence (opening)

Allogeneic hematopoietic cell transplantation (allo-HCT has been increasingly used for a variety of hematologic neoplasms and non-malignant bone marrow disorders. Eligibility for allo-HCT varies amongst institutions and is usually based on a case-by-case basis dependent upon a risk-benefit assessment, and the needs and wishes of the patient. 7

Although historically allo-HCT was offered to patients who had exhausted all other treatment modalities, currently the decision to perform a transplant is dependent upon an assessment if the transplant will offer an outcome superior to other treatment options. 7

The CMS National Coverage Determination (NCD 110.23) for Stem Cell Transplantation describes nationally covered indications for SCT, the details of which will not be fully repeated within this policy. This policy describes additional locally covered indications for allogeneic stem cell for primary refractory or relapsed Hodgkin's and non-Hodgkin's lymphomas with B-cell or T-cell origin, for whom there are no other curative intent options, and are medically necessary.

Multiple other disorders are under investigation as part of clinical trials and are not covered unless the clinical trial meets the criteria of NCD 310.1 Routine Costs in Clinical Trials.

The contractor cites 9 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2023-08-01
Current revision effective
2026-04-01
MCD version
4

The contractor lists 2 National Coverage Determinations as related: NCD 310.1 Routine Costs in Clinical Trials, NCD 110.23 Stem Cell Transplantation (Formerly 110.8.1). Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A59451 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39513 cover?

Stem cell transplantation is a process in which s tem cells are harvested from either a patient’s (autologous) or donor’s (allogeneic) bone marrow or peripheral blood for intravenous infusion. Autologous s tem cell transplantation (AuSCT) is a technique for restoring stem cell s using the patient's own previously stored cells. AuSCT must be used to effect hematopoietic reconstitution following severely myelotoxic… The full 559-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39513 apply to?

Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39513?

The companion billing and coding article A59311 lists 380 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39513?

A denial under LCD L39513 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59311's 380 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.